Burning Rock Biotech (BNR) has released an update.
Burning Rock Biotech reported a decrease in total revenues by 7.3% in the second quarter of 2024 compared to the same period in 2023, primarily due to a strategic shift from central-lab to in-hospital based testing, which saw an 11.2% revenue increase. Despite a dip in gross profit and an overall net loss, the company managed to reduce operating expenses through budget control and headcount reduction. The company remains a key player in next generation sequencing for precision oncology, with partnerships and study results presented at recent conferences.
For further insights into BNR stock, check out TipRanks’ Stock Analysis page.
